Mitochondrial Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox
|title=Mitochondrial Therapies
|image=
_caption=Mitochondrial dysfunction is a key feature of neurodegeneration
}}
Mitochondrial dysfunction is a central hallmark of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. Mitochondria provide energy for neurons, regulate calcium homeostasis, and control apoptotic pathways. Therapies targeting mitochondrial function represent a promising approach to protect neurons and slow disease progression[1].
The mitochondrial cascade hypothesis proposes that mitochondrial dysfunction is not just a downstream effect of neurodegeneration but may be a primary driver of disease pathogenesis[2]:
| Defect | Description | diseases |
|---|---|---|
| Electron transport chain deficits | Complex I deficiency particularly common | PD, AD |
| Oxidative stress | ROS accumulation damages cellular components | All neurodegenerative diseases |
| Dynamin abnormalities | Altered fusion/fission in AD and HD | AD, HD |
| Mitophagy impairment | Failed clearance of damaged mitochondria | PD, AD |
| Calcium dysregulation | Mitochondrial calcium handling impaired | AD, PD |
Alzheimer's Disease:
Parkinson's Disease:
Huntington's Disease:
Amyotrophic Lateral Sclerosis (ALS):
Coenzyme Q10 (CoQ10):
MitoQ:
EPI-743 (Vatiquinone):
Alpha-lipoic acid:
Purpose: Promote clearance of damaged mitochondria
| Agent | Mechanism | Clinical Status |
|---|---|---|
| Urolithin A | Induces mitophagy via PINK1 pathway | Phase II completed |
| Rapamycin | mTOR inhibition promotes autophagy | Off-label use |
| Nicotinamide riboside | NAD+ precursor supports mitophagy | Phase I/II |
| Spermidine | Autophagy inducer | Dietary supplement |
Urolitin A (Mitophagy):
AMPK Activators:
SIRT1 Activators:
TFEB Activators:
| Co-factor | Function | diseases |
|---|---|---|
| L-carnitine | Fatty acid transport into mitochondria | HD |
| CoQ10 | Electron transport | PD, HD, ALS |
| Alpha-ketoglutarate | TCA cycle intermediate | Research |
| PQQ | Mitochondrial biogenesis | Research |
Complex I modulators:
ATP synthase modulators:
| Trial | Compound | Phase | Outcome |
|---|---|---|---|
| QEED | CoQ10 | III | Failed primary, showed trend |
| MRC | CoQ10 | II | Slowed progression |
| MITO-PD | MitoQ | II | Ongoing |
| Trial | Compound | Phase | Outcome |
|---|---|---|---|
| 2CARE | CoQ10 | III | Negative (high dose) |
| CREST-E | Creatine + CoQ10 | II | Ongoing |
| Trial | Compound | Phase | Outcome |
|---|---|---|---|
| NCT02460679 | CoQ10 | II | Mixed results |
| NCT03427060 | EPI-743 | II | Ongoing |
Mitochondrial dysfunction involves multiple pathways, so combination therapy may be more effective than single agents.
| Combination | Rationale |
|---|---|
| CoQ10 + Creatine | Energy production + protection |
| Urolithin A + NAD+ precursors | Mitophagy + biogenesis |
| MitoQ + Exercise | Antioxidant + mitochondrial stress |
| Metformin + Lifestyle | AMPK activation + behavior change |
| Measure | diseases | Tool |
|---|---|---|
| Motor function | PD, HD | UPDRS, UHDRS |
| Cognitive function | AD, HD | MoCA |
| Functional capacity | HD | TFC |
| Survival | ALS | ALSFRS-R |
The study of Mitochondrial Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Van Houten B, Wanga V. Mitochondrial dysfunction in neurodegenerative diseases. Nat Rev Neurosci. 2006;7(9):706-719. PMID:16936646 ↩︎
Swerdlow RH. The mitochondrial cascade hypothesis. J Neuropathol Exp Neurol. 2018;77(1):3-15. ↩︎
Wang X, et al. Amyloid-beta and mitochondria: A fatal liaison in Alzheimer's disease. J Alzheimers Dis. 2020;75(s1):S45-S53. ↩︎
Park J, et al. Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and therapeutic approaches. Mol Neurobiol. 2021;58(5):2189-2204. ↩︎
Brustovetsky N, Brustovetsky T. Mitochondrial dysfunction in Huntington's disease. J Bioenerg Biomembr. 2020;52(4):263-276. ↩︎
Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapeutic agents. Ann N Y Acad Sci. 2010;1201:96-103. ↩︎
D'Amico D, et al. Urolithin A induces mitophagy and improves muscle function in aged individuals. Nat Aging. 2021;1:410-420. ↩︎